Back to Conference page
UICC World Cancer Congress 2006
Bridging the Gap: Transforming Knowledge into Action
July 8-12, 2006, Washington, DC, USA
Patients and Methods: ‘HUMA' was orally administrated to 40 oral cancer patients. In 30 (75 %) patients conventional treatment could not be initiated because of financial problems. Twenty two (55%) patients presented with a T4 cancer.
Results: Complete regression of the cancer was observed in 5 (12.5 %), marked remission in 7 (17.5 %) and partial regression in 5 (12.5%) patients respectively. No adverse effects of this alternative therapy were observed in any of these patients. One patient has so far completed 5 years' disease free survival. Seven patients relapsed after stoppage of therapy.
Conclusion: The results indicate that ‘HUMA' was effective in causing regression of oral carcinoma. In absence of conventional therapy we believe that the tumor regression observed in some patients may be due to ‘HUMA'. Proper evaluation of this alternative cancer therapy is thus required.